Rivaroxaban
- Generic Name
- Rivaroxaban
- Brand Names
- Xarelto, Rivaroxaban Accord, Rivaroxaban Viatris (previously Rivaroxaban Mylan)
- Drug Type
- Small Molecule
- Chemical Formula
- C19H18ClN3O5S
- CAS Number
- 366789-02-8
- Unique Ingredient Identifier
- 9NDF7JZ4M3
- Background
Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food. FDA approved on July 1, ...
- Indication
Rivaroxaban is indicated for the prevention of venous thromboembolic events (VTE) in patients who have undergone total hips replacements and total knee replacement surgery; prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE); to reduce risk of recurre...
- Associated Conditions
- Cardiovascular Mortality, Deep Vein Thrombosis, Deep vein thrombosis recurrent, Major Adverse Cardiovascular Events, Myocardial Infarction, Pulmonary Embolism, Recurrent Pulmonary Embolism (Disorder), Recurrent Venous Thromboembolism, Stroke, Systemic Embolism, Thrombosis, Venous Thromboembolism
- Associated Therapies
- -
Surgical Revascularization Outcomes After Oral Anticoagulation or Antiplatelets
- First Posted Date
- 2018-07-30
- Last Posted Date
- 2018-07-30
- Target Recruit Count
- 100
- Registration Number
- NCT03605433
- Locations
- 🇵🇹
Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
Non-interventional, Retrospective Cohort Study to Explore OAC Treatment in Korea
- Conditions
- Interventions
- First Posted Date
- 2018-06-28
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 64684
- Registration Number
- NCT03572972
- Locations
- 🇰🇷
Korea University Hospital, Seoul, Korea, Republic of
Rivaroxaban Once Daily Versus Dose-adjusted Vitamin K Antagonist on the Biomarkers in Acute Decompensated Heart Failure and Atrial Fibrillation (ROAD HF-AF)
- First Posted Date
- 2018-04-06
- Last Posted Date
- 2019-01-10
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 150
- Registration Number
- NCT03490994
- Locations
- 🇰🇷
Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of
Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy
- First Posted Date
- 2018-03-13
- Last Posted Date
- 2021-07-30
- Lead Sponsor
- Charite University, Berlin, Germany
- Target Recruit Count
- 1512
- Registration Number
- NCT03463317
- Locations
- 🇩🇪
Vivantes Klinik Am Urban, Kardiologie, Berlin, Germany
🇩🇪Charité Universitätsmedizin Berlin, CBF, Kardiologie, Berlin, Germany
🇩🇪Vivantes Klinikum Neukölln, Kardiologie, Berlin, Germany
Apixaban Drug Utilization Study In Stroke Prevention In Atrial Fibrillation (Spaf)
- Conditions
- Interventions
- First Posted Date
- 2018-02-22
- Last Posted Date
- 2023-06-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 51690
- Registration Number
- NCT03441633
- Locations
- 🇪🇸
IDIAP Jordi Gol, Barcelona, Cataluña, Spain
Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2018-02-09
- Last Posted Date
- 2024-02-29
- Lead Sponsor
- Lawson Health Research Institute
- Target Recruit Count
- 57
- Registration Number
- NCT03428373
- Locations
- 🇨🇦
London Health Sciences Centre, London, Ontario, Canada
Rivaroxaban With Diosmin in Long-term Treatment of Deep Vein Thrombosis
- Conditions
- Interventions
- First Posted Date
- 2018-01-29
- Last Posted Date
- 2021-02-04
- Target Recruit Count
- 90
- Registration Number
- NCT03413618
- Locations
- 🇷🇺
Clinical Hospital no.1 of the President's Administration of Russian Federation, Moscow, Russian Federation
Monotherapy Anticoagulation To Expedite Home Treatment of Venous Thromboembolism
- First Posted Date
- 2018-01-19
- Last Posted Date
- 2020-08-07
- Lead Sponsor
- Indiana University
- Target Recruit Count
- 1300
- Registration Number
- NCT03404635
- Locations
- 🇺🇸
Eskenazi Health System, Indianapolis, Indiana, United States
🇺🇸Indiana University Health Methodist Hospital, Indianapolis, Indiana, United States
The Safety and Efficacy Of Rivaroxaban and Ticagrelor for Patients With Atrial Fibrillation After Percutaneous Coronary Intervention
- Conditions
- Interventions
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2023-01-17
- Lead Sponsor
- Ottawa Heart Institute Research Corporation
- Target Recruit Count
- 40
- Registration Number
- NCT03331484
- Locations
- 🇨🇦
University of Ottawa Heart Institute, Ottawa, Ontario, Canada
A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects
- Conditions
- Interventions
- First Posted Date
- 2017-10-16
- Last Posted Date
- 2023-02-24
- Lead Sponsor
- Portola Pharmaceuticals
- Target Recruit Count
- 108
- Registration Number
- NCT03310021
- Locations
- 🇺🇸
WCCT Global, Cypress, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.